Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No 2)

Link copied
Case Copied 79 min read

FEDERAL COURT OF AUSTRALIA

Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No 2) [2013]
FCA 279

Citation: Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No 2) [2013] FCA 279
Parties: BAYER PHARMA AKTIENGESELLSCHAFT and BAYER AUSTRALIA LIMITED ACN 000 138 714 v GENERIC HEALTH PTY LTD  ACN 110 617 859 and LUPIN AUSTRALIA PTY LTD ACN 112 038 105
File number(s): NSD 236 of 2012
Judge: JAGOT J
Date of judgment: 4 April 2013
Catchwords: PATENTS – Validity – Infringement – Lack of inventive step – Obviousness – Manner of manufacture – Fair basing
Legislation: Patents Act 1990 (Cth)
Therapeutic Goods Act 1989 (Cth)
Cases cited:

Aktiebolaget Hassle v Alphapharm (2002) 212 CLR 411; [2002] HCA 59
Alpharpharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618; (2008) FCA 559
Application of Tomlinson (1966) 363F 2d 928
Bayer Pharma Aktiengelsellschaft v Generic Health Pty Ltd [2013] FCA 226)
Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65
Commissioner of Patents v Microcells Ltd (1959) 102 CLR 323
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (No 1) (2004) 217 CLR 274; [2004] HCA 58
NationalResearch Development Corporationv Commissioner of Patents (1959) 102 CLR 252
Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157
Populin v HB Nominees Pty Ltd (1982) 41 ALR 471
Pfizer Overseas Pharmaceuticals v Eli Lilly & Co (2005) 5 ALR 416; [2005] FCAFC 224
Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262; [1981] HCA 12

Date of hearing: 11 - 14 and 18 - 22 March
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 107
Counsel for the First and Second Applicants: D Shavin QC with Helen Rofe
Counsel for the First and Second Respondents: A H Bowne SC with A D B Fox
Solicitor for the First and Second Applicants: Davies Collison Cave Law
Solicitor for the First and Second Respondents: K & L Gates

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 236 of 2012

BETWEEN:

BAYER PHARMA AKTIENGESELLSCHAFT
First Applicant

BAYER AUSTRALIA LIMITED ACN 000 138 714
Second Applicant

AND:

GENERIC HEALTH PTY LTD  ACN 110 617 859
First Respondent

LUPIN AUSTRALIA PTY LTD ACN 112 038 105
Second Respondent

JUDGE:

JAGOT J

DATE OF ORDER:

4 APRIL 2013

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The parties are to file and serve proposed orders reflecting these reasons for judgment within seven days of the date of these orders.

2.The proceeding is to be listed on a date not less than seven days thereafter such date being determined in consultation with the parties.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 236 of 2012

BETWEEN:

BAYER PHARMA AKTIENGESELLSCHAFT
First Applicant

BAYER AUSTRALIA LIMITED ACN 000 138 714
Second Applicant

AND:

GENERIC HEALTH…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 279
Decision Date

CaseChat Overview and Summary

Bayer Pharma Aktiengesellschaft brought proceedings against Generic Health Pty Ltd, alleging that Generic Health had infringed claims 3 and 11 of Bayer's patent for a pharmaceutical composition. Bayer claimed that Generic Health had supplied a product that infringed the patent by supplying a formulation that contained a specific active pharmaceutical ingredient (API) and did not meet the criteria set out in the patent claims. Generic Health denied that it had infringed the patent and argued that the patent was invalid on the basis of lack of inventive step and obviousness. The court was required to determine whether the patent was valid and whether Generic Health had infringed the patent.

The court found that the patent was valid and that Generic Health had infringed claims 3 and 11 of the patent. The court held that the invention was not merely finding the means to ensure that the API dissolved rapidly, but rather finding a suitable formulation by which the API was bioavailable and not degraded in the stomach. The court found that the expert evidence of Dr Rowe and Professor Davies was more compelling than that of Dr Walters, and that their experience and expertise in formulation supported their opinions that the invention was not obvious. The court also found that the evidence did not support a finding of obviousness on any view.

The court ordered that the parties were to file and serve proposed orders reflecting these reasons for judgment within seven days of the date of the orders, and that the proceeding was to be listed on a date not less than seven days thereafter. The parties were to consult and determine the date in consultation with each other. Entry of orders was to be dealt with in accordance with Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The parties are to file and serve proposed orders reflecting these reasons for judgment within seven days of the date of these orders.

2. The proceeding is to be listed on a date not less than seven days thereafter such date being determined in consultation with the parties.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

In these circumstances the respondents’ characterisation of the invention cannot be accepted. The invention is not merely finding the means to ensure that DRSP dissolves rapidly. The invention is the finding of a suitable formulation by which the DRSP is bioavailable and not degraded in the stomach. The problem which would have confronted the hypothetical formulation is that DRSP is both poorly soluble and acid labile. On the one hand the formulator would know that they had to improve the dissolution rate of DRSP but on the other hand they would know that improving the dissolution rate would mean even greater exposure of the DRSP to degradation and transformation into its inactive isomer in the acid environment of the stomach. The invention lies in the creation of a rapidly dissolving formulation of DRSP which substantially reduces isomerisation of the DRSP in the stomach leading to high bioavailability.FACTS As I have said, the facts of this case do not support a finding of obviousness on any view. Leaving aside for the moment information which might be able to be considered under s 7(3) of the Patents Act there are numerous factors which weigh against accepting the respondents’ contention of obviousness. First, the expert evidence has to be weighed up having regard to the fact that Dr Walters has not been involved in the task of formulating any drug, let alone a new API, since the early 1970s and her formulation experience from her period of work in industry is limited. Although I accept that this does not mean her evidence is irrelevant, I do not accept that her experience as a regulator gave her a unique insight into how the hypothetical formulator or drug development team would proceed. As for Dr Rowe, while he has had direct formulation experience, his experience does not extend to the identification of the appropriate dosage form for a new API. Although the respondents submitted that Professor Davies’ formulation experience should be understood as having only commenced in 1997, two years before the priority date, this suggestion was never put to Professor Davies. This is despite the fact that in his affidavit Professor Davies said that his scientific, academic and industrial knowledge experience and expertise made him well qualified to give the opinions in his affidavit. That experience included co-founding and being the head of the Laboratory of Biophysics and Surface Analysis, a Research Division of the School of Pharmacy at the University of Nottingham until 2008 in circumstances where that laboratory “has been involved in the development of a number of pharmaceutical formulations for multi-national pharmaceutical companies”. Professor Davies also said he was the founder of a company in 1997 which provides consulting services to the pharmaceutical industry providing “customised formulation characterisation and development across a broad range of therapies, mainly containing small molecules, Active Pharmaceutical Ingredients”. Professor Davies also worked as a pre-registration pharmacy graduate at a hospital in 1981 and held a research and development position at Roche Products Limited. Faced with this information in his affidavit, any challenge to Professor Davies’ expertise as a person directly involved in formulation had to be put to Professor Davies directly. In other words, in weighing up the competing expert opinions it is relevant that Professor Davies’ experience involves extensive direct engagement with the formulation process as a member of a research drug development team which, according to his oral evidence, extends to new APIs.

Evidence

Evidence Before The Court

Section 117 deals with infringement of a patent by supply in these terms:(1)If the use of a product by a person would infringe a patent, the supply of that product by one person to another is an infringement of the patent by the supplier unless the supplier is the patentee or licensee of the patent. (2)A reference in subsection (1) to the use of a product by a person is a reference to: (a)if the product is capable of only one reasonable use, having regard to its nature or design – that use; or (b)if the product is not a staple commercial product--any use of the product, if the supplier had reason to believe that the person would put it to that use; or (c)in any case – the use of the product in accordance with any instructions for the use of the product, or any inducement to use the product, given to the person by the supplier or contained in an advertisement published by or with the authority of the supplier. OVERVIEW OF THE EVIDENCEJAMES ROWE Dr Rowe has had over 30 years’ experience in the pharmaceutical industry having obtained a Bachelor of Pharmacy degree in 1966, a Masters of Science in 1976, and a PhD in Pharmaceutics in 1980. Throughout this period he was involved in the development of new pharmaceutical products including the evaluation and testing of new drug formulations and now provides services as a consultant to the pharmaceutical industry. However, Dr Rowe has not carried out preformulation studies for a new API or been involved in decisions about dosage forms for a new API. Dr Rowe explained that solid dosage forms commonly used since the 1960s to deliver API are known as immediate release, extended or controlled release, and delayed release preparations. Immediate release preparations are designed to release the API with minimum delay after ingestion. Extended or controlled release preparations are designed to release the API over a period of time. Delayed release preparations, which are enteric coated formulations, are designed so that the dosage form remains intact until after it passes the pylorus in the stomach and enters the small intestine. Dr Rowe also explained that a pharmaceutical composition is composed of an API and non-pharmaceutically active ingredients, the latter being known as excipients. Excipients are able to be classified according to function and include bulkers or fillers, disintegrants, binders, lubricants and coating excipients. Dr Rowe said that his first introduction to enteric coatings was in 1969 and they were reasonably common in Australia by the 1970s. By 1999 the use of enteric coatings was very common. According to Dr Rowe the variability in effect of enteric coatings is huge. He said that he had never formulated an enteric coating formulation where he did not know the oral bioavailability of an immediate release oral dosage form. According to Dr Rowe:The normal procedure is to determine the oral bioavailability of the API as a first step. This enables the formulator to assess if an enteric coat is in fact required. It also evaluates the effectiveness of an enteric coated formulation over a conventional immediate release formulation.

Decision

Reasons for decision

For these reasons the applicants have established infringement of claims 3 and 11 of the patent by the respondents.CONCLUSIONS For the reasons set out above the respondents have not established that claims 3 and 11 of the patent are invalid. The applicants have established that the respondents have infringed claims 3 and 11 of the patent. Orders should be made accordingly.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.